Evidence map›Paper›PMID 39308028›Full record

Trial reportBritish journal of haematology2024

Acalabrutinib alone or in combination with rituximab for follicular lymphoma: An open-label study.

Paolo Strati, Rebecca Champion, Morton Coleman, Sonali M Smith, Parameswaran Venugopal, Peter Martin, Andrew Wood, Kara Miller, Beth Christian

Abstract readClinical Trial, Phase IClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of haematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Paolo StratiThe University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-7445-1459
Rebecca ChampionNorton Cancer Institute, Louisville, Kentucky, USA.
Morton ColemanClinical Research Alliance/Weill Cornell Medicine, New York, New York, USA.
Sonali M SmithThe University of Chicago Medical Center, Chicago, Illinois, USA.
Parameswaran VenugopalRush University Medical Center, Chicago, Illinois, USA.
Peter MartinWeill Cornell Medical College, New York Presbyterian Hospital, New York, New York, USA.ORCID https://orcid.org/0000-0001-7813-1551
Andrew WoodAstraZeneca, Cambridge, UK.
Kara MillerAstraZeneca, South San Francisco, California, USA.
Beth ChristianThe Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.

Funding

AstraZeneca
6 · The paper itself

Abstract

Acalabrutinib is a selective, second-generation Bruton tyrosine kinase inhibitor. In this open-label, parallel-group study, patients with relapsed/refractory (R/R) follicular lymphoma (FL) were randomised to either acalabrutinib monotherapy or acalabrutinib plus rituximab. An additional cohort of patients with treatment-naive (TN) FL received only the acalabrutinib-rituximab combination. Acalabrutinib-rituximab was well tolerated and active in R/R and TN FL; in the TN cohort the overall response rate was 92.3% with most remissions lasting over 4 years. Acalabrutinib monotherapy was also well tolerated and active in R/R FL. These results support further study of acalabrutinib alone and in combination with rituximab in FL.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBenzamidesLymphoma, FollicularPyrazinesRituximabAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedTreatment OutcomeacalabrutinibBenzamidesPyrazinesRituximabB‐cell lymphomaBruton tyrosine kinasenon‐Hodgkin lymphoma

Identifiers

PMID39308028
PMCPMC11637741

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.